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Abstract
Our previous study shows that inhibiting activator protein one (AP1) transcription factor function in murine epidermis,
using dominant-negative c-jun (TAM67), increases cell proliferation and delays differentiation. To understand the
mechanism of action, we compare TAM67 impact in mouse epidermis and in cultured normal human keratinocytes. We
show that TAM67 localizes in the nucleus where it forms TAM67 homodimers that competitively interact with AP1
transcription factor DNA binding sites to reduce endogenous jun and fos factor binding. Involucrin is a marker of
keratinocyte differentiation that is expressed in the suprabasal epidermis and this expression requires AP1 factor
interaction at the AP1-5 site in the promoter. TAM67 interacts competitively at this site to reduce involucrin expression.
TAM67 also reduces endogenous c-jun, junB and junD mRNA and protein level. Studies with c-jun promoter suggest
that this is due to reduced transcription of the c-jun gene. We propose that TAM67 suppresses keratinocyte
differentiation by interfering with endogenous AP1 factor binding to regulator elements in differentiation-associated
target genes, and by reducing endogenous c-jun factor expression.
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Introduction
Activator protein one (AP1) transcription factors are a family of
jun and fos proteins that form jun-jun and jun-fos homo- and
heterodimers, and these complexes interact with AP1 factor DNA
binding sites to regulate gene expression [1–4]. The AP1 factor
family includes c-jun, junB, junD, c-fos, FosB, Fra-1 and Fra-2.
These proteins are implicated in control of keratinocyte pro-
liferation [5–7], differentiation [8–10], apoptosis [11,12], and
transformation [13–16]. The importance of these proteins is
confirmed by in vivo studies [13,17–25]. Analysis of the role of
these proteins in epidermis is complicated because AP1 proteins
display context-dependent functions and because multiple family
members are expressed.
An altered form of c-jun, which is truncated to remove the N-
terminal transactivation domain, has been used to study AP1
factor function [26]. Deletion of the c-jun transactivation domain
creates a dominant-negative form of the protein (TAM67) that
inhibits AP1 factor function [26]. TAM67 has been used in
a number of systems. TAM67 expression in lung cancer in mice
[27,28] and in nasopharyngeal carcinoma inhibits cell growth by
altering cell cycle protein expression [29]. TAM67 inhibits
growth of MCF-7 breast cancer cells [30], and halts HT-1080
cell proliferation in G1 phase [31]. TAM67 has also been used to
study the impact of AP1 factor signaling on cell differentiation.
Inhibition of AP1 factor function in neuroblastoma cells
suppresses nerve growth factor-dependent differentiation [32].
In melanoma cells, induction of the melanoma differentiation
associated genes is increased by AP1 factors and inhibited by
TAM67 [33], and TAM67 also inhibits differentiation in
monocytic leukemia cells [34].
We [35,36] and others [37–43] have used TAM67 to study AP1
factor function in keratinocytes. These studies show that TAM67
inhibits keratinocyte differentiation [35,36]. Cell culture based
studies in human primary foreskin keratinocytes show that AP1
factors are required for expression of markers of terminal
differentiation and that inhibition of AP1 factor function with
TAM67 suppresses these responses [10,36,44]. We have also
recently shown that expression of TAM67 in vivo in suprabasal
mouse epidermis results in delayed and incomplete epidermal
differentiation [35].
However, the molecular mechanism of TAM67 action in these
models is not fully understood. In the present study we examine
the mechanism of TAM67 action on AP1 factor function in
epidermal keratinocytes. These studies indicate that TAM67
homodimer binds to AP1 factor DNA binding sites in human
keratinocytes to inhibit jun and fos factor binding, and also
reduces the mRNA and protein level of endogenous jun family
members. In the case of c-jun this is via inhibition of transcription.
Moreover, TAM67 binding to the AP1-5 binding site of the
involucrin (hINV) promoter reduces expression of involucrin,
a keratinocyte differentiation marker, in cultured keratinocytes.
We further show that TAM67 in murine epidermis reduces
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36941involucrin (and loricrin) gene expression and reduces binding of
endogenous AP1 factors to AP1 factor binding elements.
Results
TAM67 is a truncated form of c-jun that lacks the amino
terminal transactivation domain and is not transcriptionally active
[26] (Fig. 1A). In the present study we utilize TAM67 as a tool to
study AP1 factor function in normal human keratinocytes. To
initiate these studies, we monitored TAM67-FLAG expression.
Fig. 1B shows that TAM67-FLAG is expressed in keratinocytes
and Fig. 1C shows that, as expected of a nuclear transcriptional
regulator, TAM67-FLAG accumulates in the nucleus.
AP1 factors are key regulators of function in keratinocytes [45–
47]. To understand the impact of TAM67 on AP1 factor function,
we monitored endogenous AP1 factor level in TAM67-expressing
cells. Fig. 2A shows a reduction in c-jun, junB and junD but no
change in Fra-1, Fra-2 or c-fos level in TAM67 expressing cells,
suggesting that TAM67 reduces the level of a subset of AP1
factors. To assess the mechanism causing c-jun, junB and junD
reduction, we monitored mRNA level using quantitative RT-
PCR. The level of c-jun, junB and junD encoding mRNA is
reduced in TAM67 expressing cells, indicating that part of the
reason for loss of these factors is a reduction in mRNA level
(Fig. 2B). In contrast, the level of RNA encoding fos family
members (Fra-1, Fra-2, c-fos) is not altered. We next examined the
ability of TAM67-FLAG to interact with other AP1 factors by
testing the ability of TAM67-FLAG to co-precipitate individual
AP1 factors in keratinocytes. As shown in Fig. 2C, anti-FLAG
precipitation of TAM67-FLAG co-precipitates Fra-1, Fra-2 and c-
fos. In contrast, junB and junD did not co-precipitate, which is
expected considering that these proteins are reduced in level in
TAM67-expressing cells (Fig. 2A). In spite of the reduction in total
c-jun level (Fig. 2A), sufficient c-jun appears to remain and
interacts with TAM67-FLAG (Fig. 2C). We next monitored the
impact on nuclear AP1 factor level. Fig. 2D shows that TAM67
expression is associated with reduced nuclear c-jun, junB and
junD. In contrast, nuclear c-fos, Fra-1 and Fra-2 levels are not
affected.
Figure 1. TAM67-FLAG expression in keratinocytes. A Comparison of c-jun and TAM67 structure. The numbers are indicated in amino acids.
The transactivation, DNA binding and leucine zipper domains are indicated. The TAM67 truncated protein is FLAG epitope tagged as indicated. B/C
TAM67-FLAG is expressed in keratinocytes. Normal human keratinocytes were infected with 10 MOI of tAd5-EV or tAd5-TAM67-FLAG with 5 MOI of
Ad5-TA. After 24 h the cells were fixed for immunostaining and extracts were prepared for immunoblot with anti-FLAG. Similar results were observed
in each of three repeated experiments.
doi:10.1371/journal.pone.0036941.g001
TAM67 Impact on AP1 Signaling
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As shown above, c-jun, junB and junD protein and mRNA
levels are reduced in TAM67-expressing cells. To gain insight
regarding the mechanism, we used c-jun as a model. We examined
the impact of TAM67 on c-jun mRNA level and promoter activity
in a side-by-side comparison. Fig. 3A shows that TAM67 reduces
c-jun encoding mRNA by more than 50%. To gain insight into the
mechanism, we monitored the impact of TAM67 on activity of a c-
jun promoter construct in which nucleotides 21780/+731 is
linked to luciferase (Fig. 3B). Our studies show that TAM67
reduces promoter activity by 50% in keratinocytes. In contrast, the
same promoter in which the key AP1 factor binding sites are
mutated, 21780/+731(AP1m) [48], displays basal activity and is
not regulated by TAM67. Fig. 3C shows the structure of the
promoter constructs. These findings suggest that c-jun level is
reduced by a transcriptional mechanism that requires AP1 factor
binding sites in the c-jun promoter upstream regulatory region.
TAM67-FLAG Inhibits AP1 Factor Binding to AP1
Consensus DNA Binding Element
Gel mobility shift and supershift analysis, using a consensus
AP1 binding probe, was performed to investigate the effect of
Figure 2. Impact of TAM67-FLAG on AP1 factors. Keratinocytes were infected with empty (EV) or TAM67-FLAG encoding adenovirus and after
24 h cells were harvested and extracts prepared. A Total extracts were electrophoresed for immunoblot detection of the indicated proteins. B
TAM67-FLAG suppresses jun factor mRNA level. At 24 h post-infection with EV or TAM67-FLAG encoding virus, mRNA was prepared for detection by
quantitative PCR. The bars are mean 6 SD and the asterisks indicate a significant reduction (p,0.005, n=3). C Total extract (200 mg) was
immunoprecipitated with anti-FLAG and the immunoprecipitate was electrophoresed for immunoblot to detect the indicated jun and fos proteins. D
Nuclear extract was prepared and the level of each indicated protein was measured by immunoblot. Similar results were observed in three
experiments.
doi:10.1371/journal.pone.0036941.g002
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shows a gel shift using
32P-labeled AP1 consensus binding site
oligonucleotide and human foreskin keratinocyte nuclear extract.
Shifted bands appear at increased intensity and free probe appears
at reduced intensity in nuclear extracts prepared from TAM67-
FLAG expressing cells (lanes 3, 5 and 9). This is caused by an
increase in total cellular AP1 site binding capacity due to the
presence of TAM67. As expected, addition of anti-FLAG results in
appearance of a supershifted band only in extracts from TAM67-
FLAG expressing cells (lane 5, asterisk). We next incubated
nuclear extract from control and TAM67-expressing cells with
anti-c-jun, junB, junD, Fra-1, Fra-2, c-fos or fosB. Supershifted
bands are observed for each AP1 factor. The most obvious
supershifts were observed for c-jun, junD, Fra-1, Fra-2 and c-fos
(Fig. 4B). The amount of supershifted DNA is reduced in
TAM67-expressing cells, demonstrating that TAM67 competes for
endogenous AP1 factor binding to the AP1c element (Fig. 4B).
We also examined the ability of TAM67 to form dimers. Nuclear
extract from TAM67-FLAG expressing cells was crosslinked with
disuccinimidyl suberate (DSS) prior to denaturing gel electropho-
resis. Fig. 4C shows the presence of a TAM67 dimer, in DSS-
treated extracts, migrating at 54 kDa. There are also higher
molecular weight forms (brackets) which most likely represent
TAM67 crosslinking to endogenous AP1 factors. However, the
major band appears as a TAM67 homodimer. These findings
suggest that TAM67 homodimers interact with AP1 binding sites
to inhibit binding of endogenous AP1 factors. It also suggests that
a TAM67 homodimer may be the major AP1 site interacting
species in these cells.
TAM67-FLAG Inhibits hINV Gene Expression
We next investigated the impact of TAM67 on AP1-regulated
gene expression using involucrin (hINV) as an AP1 responsive
gene [10]. Involucrin is a keratinocyte differentiation marker and
is known to be increased by AP1 transcription factor signaling
[25,47,49–51]. Control and TAM67-FLAG expressing keratino-
cytes were harvested and the level of hINV protein and mRNA
was measured. Fig. 5A shows a TAM67-dependent reduction in
hINV protein and mRNA. To assess the mechanism, we
monitored the impact on hINV promoter activity. Three promoter
constructs were used and keratinocytes were treated with TPA,
a strong inducer of AP1-dependent hINV promoter activity
[47,49]. The hINV basal promoter, which encodes 41 nucleotides
upstream of the transcription start site [47] and no AP1 sites, is not
regulated by TAM67 or TPA (Fig. 5B). In contrast, pINV-241,
which encodes the proximal regulatory region, and pINV-2473,
which encodes both the proximal and distal regulatory regions
[23,47], are responsive to TPA and basal and TPA-stimulated
promoter activity is inhibited by TAM67. The proximal and distal
regulatory regions encode regulatory elements required for
promoter activity in cultured keratinocytes [47] and involucrin
expression in vivo [47,49]. These experiments indicate that TAM67
inhibits differentiation-associated AP1-dependent transcriptional
events in keratinocytes.
TAM67-FLAG Binds to the AP1-5 Site of hINV Gene
Promoter
AP1 factors regulate transcription of hINV via binding to the
proximal and distal AP1 sites in the hINV promoter [25,47,49–
51]. In particularly, the AP1-5 site in the distal promoter is
absolutely required for involucrin gene expression in vivo [22–25].
We therefore examined the impact of TAM67 on AP1 factor
interaction at the AP1-5 site. Fig. 6 shows gel mobility shift
analysis of AP1 factor binding to the hINV promoter AP1-5 site.
Fig. 6A shows that the presence of TAM67-FLAG markedly
increases the intensity of the gel shifted band (compare lanes 2 and
3) and that incubation with anti-FLAG produces a strong
supershifted band only in cells expressing TAM67-FLAG (com-
pare lanes 4 and 5). Moreover, the binding is competed by
incubation with a 50-fold molar excess of radioinert AP1-5
oligonucleotide (see lanes 6 and 7), but a 50-fold excess of AP1-
5 m does not compete (lane 8). We next examined the impact of
TAM67 on endogenous AP1 factor interaction with AP1-5. As
shown in Fig. 6B, supershifted bands (asterisks) are observed
when extracts are incubated with anti-c-jun, junB, junD, Fra-1,
Fra-2 and c-fos, and this interaction is reduced in the presence of
TAM67-FLAG. Fos-B was not detected. The low signal intensity
of the shifted bands is consistent with previous reports [47].
To further assess the in vivo impact of TAM67 we used
chromatin immunoprecipitation. Nuclear extracts from TAM67-
FLAG positive and negative keratinocytes were prepared for ChIP
analysis using a primer set that targets the AP1-5 binding site
(22218/22005) and a second primer set that targets a region of
the promoter lacking an AP1 factor binding site (21040/2919).
Figure 3. TAM67 suppresses c-jun promoter activity. A TAM67
reduces c-jun mRNA. Keratinocytes were infected with empty (EV) or
TAM67-FLAG encoding adenovirus (10 MOI) and after 24 h mRNA was
prepared and c-jun mRNA level was measured by quantitative PCR. B
TAM67 suppresses c-jun promoter activity. Keratinocytes were trans-
fected with 1 mg of the indicated c-jun promoter luciferase reporter
construct and 1 mg of pcDNA3 (EV) or pcDNA3-TAM67-FLAG (TAM67-
FLAG). After 24 h the cells were harvested and assayed for luciferase
activity. The values in both plots are mean + SD and the asterisks
indicate a significant reduction (p,0.005, n=3). C Map of c-jun
promoter region. The promoter constructs encode nucleotides 21780
to +731 with the transcription start site at +1. c-jun(21780/+731) is the
wild-type intact promoter and c-jun(21780/+731)-AP1m is a construct
in which the critical AP1 sites are eliminated by mutation [48]. LUC
indicates the luciferase gene. The numbers are given in nucleotides.
doi:10.1371/journal.pone.0036941.g003
TAM67 Impact on AP1 Signaling
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36941Figure 4. TAM67-FLAG inhibits AP1 factor binding to AP1 consensus DNA binding element. Keratinocytes were infected with 10 MOI
tAd5-EV or tAd5-TAM67-FLAG and after 24 h nuclear extracts were prepared. A AP1 factors interact with AP1 consensus DNA element. Nuclear
extracts were incubated with AP1c-P
32 without or with a 50-fold molar excess of Sp1c or AP1c oligonucleotides, or anti-FLAG antibody and
electrophoresed on a 6% acrylamide non-denaturing gel. FP indicates free probe and NE is nuclear extract. The arrow indicates the major shifted
band and asterisks indicate migration of supershifted complexes. AP1c and Sp1c encode consensus AP1 and Sp1 binding elements. B TAM67-FLAG
TAM67 Impact on AP1 Signaling
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anti-FLAG. Fig. 6C shows that TAM67-FLAG is substantially
enriched at the AP1-5 binding site (nucleotides 22218/22055) as
compared to the control DNA segment that lacks an AP1 binding
site (nucleotides 21040/2919), suggesting TAM67 interaction at
the hINV promoter AP1-5 site in vivo.
TAM67 Impact on AP1 Factors in vivo
We previously described TAM67-rTA mice in which TAM67-
FLAG expression can be induced in the suprabasal epidermis by
addition of doxycycline to the drinking water [35]. Expression of
TAM67 in this tissue would be expected to reduce expression of
AP1 factor-regulated genes. To assess this, we compared
expression of two AP1-factor regulated genes, involucrin and
loricrin [10,52,53]. TAM67-rTA mice were treated for three days
with doxycycline and total epidermal extracts were prepared to
detect involucrin and loricrin. Consistent with the finding that
involucrin expression is reduced in TAM67-expressing cultured
keratinocytes, we find that involucrin level is reduced in TAM67
expressing mouse epidermis (Fig. 7A). We also show that loricrin
protein level is reduced. Loricrin expression is also AP1 factor
signaling dependent [52].
We next examined the impact of TAM67 on endogenous AP1
factor DNA binding in mouse epidermis nuclear extracts. Fig. 7B
shows an increase in the quantity of shifted AP1c-P
32 probe in
extract prepared from TAM67-expressing epidermis. This binding
is specifically reduced by addition of excess radioinert AP1c, but is
not competed by Sp1 consensus sequence. Moreover, TAM67-
FLAG binding to AP1c-P
32 is confirmed by anti-FLAG supershift
(Fig. 7B). We also examined the impact of TAM67 on
endogenous AP1 factor binding to DNA. The supershift analysis
in Fig. 7C shows that TAM67 binding to the AP1 consensus
element reduces c-jun, junB and junD interaction, with a strong
reduction observed for junD. In contrast, Fra-2 and c-fos
interaction is not altered by TAM67 and interaction of Fra-1
and FosB is below the limits of detection.
Discussion
We recently expressed dominant-negative c-jun in murine
epidermis and observed significant changes in epidermal pheno-
type [35]. These changes included increased cell proliferation,
delayed differentiation and reduced tumor formation [35]. We
presume that TAM67 is impacting AP1 target genes in this tissue
and so in the present study we examine the TAM67 mechanism of
action in more detail. We studied the role of dominant-negative c-
jun (TAM67) in human epidermal keratinocytes and in an in vivo
murine keratinocyte model of differentiation.
In cultured human keratinocytes TAM67-FLAG was detected
in punctate foci in the center of the nucleus. Expression of TAM67
produced profound changes in AP1 transcription factor function.
The first change we observed was a reduction in c-jun, junB and
junD protein and mRNA level. The decrease in mRNA encoding
the jun factors could be due to a reduction in mRNA stability or to
a reduction in transcription. Further study with the c-jun promoter
upstream regulatory region revealed a TAM67-dependent re-
duction in promoter activity. This reduction required the presence
reduces AP1 factor binding to DNA. Nuclear extracts were incubated with AP1c-P
32 in the absence or presence of c-jun, junB, junD, Fra-1, Fra-2, c-fos,
or fosB antibodies, and electrophoresed on a 6% acrylamide non-denaturing gel. Arrows indicate shifted band and asterisks supershifted bands. FP
indicates free probe. C TAM67-FLAG forms homodimers and heterodimers. Nuclear extracts were treated with or without DSS crosslinker prior to
electrophoresis on a denaturing 8% polyacrylamide gel and TAM67-FLAG was detected by anti-FLAG immunoblot. Identical results were observed in
three repeated independent experiments.
doi:10.1371/journal.pone.0036941.g004
Figure 5. TAM67-FLAG inhibits hINV gene expression. A TAM67
reduces hINV protein and mRNA level. Keratinocytes were infected with
indicated MOI of tAd5-EV or tAd5-TAM67-FLAG and after 48 h extracts
were prepared to detect hINV protein by immunoblot and mRNA by
quantitative PCR. The values are mean 6 SD and the asterisks indicate
a significant reduction using student’s t-test, n =3 (p,0.001). B TAM67
suppresses AP1 factor-dependent promoter activity. Keratinocytes were
transfected with the indicated hINV reporter constructs in the presence
of empty pcDNA3 vector or pcDNA3-TAM67-FLAG and treated 24 h
with or without 50 ng/ml TPA prior to preparation of extracts and assay
of luciferase activity. The values are mean 6 SEM and the asterisks
indicate a significant reduction using student’s t-test, n=3 (p,0.001).
doi:10.1371/journal.pone.0036941.g005
TAM67 Impact on AP1 Signaling
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These findings are consistent with previous reports indicating that
AP1 factor auto-regulate via a feedback loop [48,54–57]. Our
findings suggest that TAM67 binds to these elements, displacing
other AP1 factors, and thereby suppresses c-jun transcription. In
contrast, it is interesting that level of the fos family members (Fra-
1, Fra-2 and c-fos) is not altered by TAM67. The loss of jun factors
is also reflected in co-precipitation experiments. Fra-1, Fra-2 and
c-fos co-precipitate with TAM67-FLAG, but junB and junD do
not. Presumably, the reduction in junB and junD co-precipitation
is due to reduced expression of these proteins. Surprisingly, c-jun,
which is markedly reduced in level, does co-precipitate with
TAM67. Perhaps c-jun homodimer formation is favored and
TAM67, which retains the leucine zipper domain required for
dimerization [26], may seek out and interact with residual c-jun in
the cells.
An interesting finding is that the population of jun family
transcription factors is highly depleted in TAM67-positive
keratinocytes. This feature has not been previously appreciated.
Since AP1 factor signaling requires jun family members as
Figure 6. TAM67 binds to the AP1-5 site of hINV gene promoter. Keratinocytes were infected with 10 MOI tAd5-EV or tAd5-TAM67-FLAG and
after 24 h nuclear extracts were prepared for gel shift. A TAM67 interaction with hINV promoter AP1-5 site. Nuclear extracts were incubated with
AP1-5-P
32 with or without a 50-fold molar excess of AP1-5 or AP1-5 m oligonucleotide, or anti-FLAG antibody, and electrophoresed on a 6%
acrylamide non-denaturing gel. FP indicates free probe and NE is nuclear extract. The arrow indicates the major shifted bands and asterisks indicate
supershifted bands. AP1-5 is an oligonucleotide encoding the AP1-5 site of hINV promoter. AP1-5 m is an AP1-5 mutant that does not bind AP1
transcription factors [47]. B TAM67 inhibits AP1 factor interaction with AP1-5. Nuclear extracts were incubated with AP1-5-P
32 in the absence or
presence of c-jun, junB, junD, Fra-1, Fra-2, c-fos, or fosB specific antibodies, and electrophoresed on a 6% acrylamide non-denaturing gel. Arrows
indicate major shifted band and asterisks indicate supershifted bands. FP is free probe. C ChIP analysis reveals TAM67 presence at the hINV upstream
regulatory region AP1-5 site in vivo. Nuclear extracts were prepared for ChIP analysis and incubated with anti-IgG or anti-FLAG and the precipitated
DNA was analyzed for AP1-5 site encoding sequences. The values are mean 6 SD (n=3, p,0.001) and the asterisk indicates a significant increase
compared to all other groups. Nucleotides 22218/22055 encodes the AP1-5 site and nucleotides 21040/2919 is a region of the hINV upstream
regulatory region that lacks an AP1 site.
doi:10.1371/journal.pone.0036941.g006
TAM67 Impact on AP1 Signaling
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expected to severely limit AP1 factor signaling. An equally
interesting feature is that expression of fos family members is not
reduced. This suggests that fos family proteins are not regulated by
an AP1 factor-dependent feedback loop in this system.
Second, we examined the impact of TAM67 on AP1 factor
interaction with DNA. DNA gel shift experiments indicate that
TAM67-FLAG interacts with the AP1 consensus DNA sequence,
and that TAM67, at the level we achieve in these experiments,
substantially reduces interaction of endogenous AP1 factors with
DNA binding sites. Previous studies suggest that TAM67 forms
transcriptionally inactive heterodimers with jun and fos family
members [26]. These factors bind to the promoter of target genes,
but are not able to activate transcription. This mechanism, called
transcriptional quenching, leads to reduced target gene expression
[26]. Our findings also suggest an additional mechanism. Protein-
Figure 7. Impact of TAM67 on AP1 factors in vivo. TAM67-rTA mice were treated with (+) or without (2) 2 mg/ml doxycycline in drinking water
for 3 days. A Murine epidermis was collected free of the dermis by high temperature separation as previously described [35]. Total extract was
prepared for immunoblot to detect the indicated proteins. TAM67-FLAG was detected with anti-FLAG. B Interaction of TAM67 with AP1 site
consensus element. Nuclear extracts were prepared from epidermis and incubated with AP1c-P
32 and other probes as indicated. FP indicates free
probe, NE indicates nuclear extract. Similar results were observed in each of three experiments. C Impact of TAM67 on interaction of endogenous AP1
factors with AP1 site element. Nuclear extracts were prepared from TAM67-negative and TAM67-expressing epidermis and incubated with the AP1c-
P
32 and antibodies as indicated. The complexes were then separated on a non-denaturing 6% polyacrylamide gel. FP indicates free probe and NE is
nuclear extract. Note the reduction in jun factor binding in the presence of TAM67-FLAG (left panel). We did not observe a significant reduction in fos
factor interaction in the presence of TAM67 (right panel).
doi:10.1371/journal.pone.0036941.g007
TAM67 Impact on AP1 Signaling
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TAM67-FLAG homodimers are preferentially formed in these
cells, and we suspect that this homodimer is a major AP1 factor
complex that interacts with DNA. This would suggest that a major
mechanism whereby TAM67 inhibits AP1 target gene expression
in keratinocytes is TAM67 homodimer interaction with DNA to
block endogenous AP1 factor access to these sites. It is also clear,
as reported previously [26], that TAM67 forms heterodimers with
jun and fos proteins, to form inactive complexes that quench
activity of the complex. Thus, two mechanisms are possible:
a blocking action wherein the TAM67 homodimer binds to DNA
to block endogenous AP1 factor interaction with AP1 sites, and
a quenching action wherein TAM67 inhibits the transactivation
potential of endogenous AP1 factors by forming inhibitory
TAM67:jun and TAM67:fos heterodimers (Fig. 8). Our studies
favor the blocking mechanism involving TAM67 homodimers.
In addition, we examined the impact of TAM67 on an
important AP1 transcription factor-regulated target, involucrin.
Involucrin is a marker of suprabasal differentiation in epidermis
that is regulated by a MAP kinase cascade [36,47]. Activation of
this cascade leads to AP1 factor interaction with specific DNA
binding elements on the hINV promoter to drive expression [23–
25]. A key DNA binding site that is required for involucrin
expression, both in cultured keratinocytes and in vivo, is the AP1-
5 DNA binding site located in the distal regulatory region of the
hINV gene promoter [36,47,50]. We show that TAM67 reduces
hINV mRNA and protein level in cultured keratinocytes.
Moreover, hINV promoter activity is also reduced, suggesting
that TAM67 is inhibiting AP1 factor-dependent transcription.
We confirmed TAM67 interaction with AP1-5 transcription
factor binding site in the hINV promoter by gel mobility shift
and chromatin IP. These findings confirm the important role of
the AP1-5 binding site in driving hINV gene expression [22–25].
The fact that this is associated with reduced binding of AP1
factor at this site, as measured by gel mobility supershift assay,
suggests that TAM67 is displacing these factors by competition.
We also examined the impact of TAM67 expression on
involucrin protein level in TAM67-expressing murine epidermis.
We compared control mice (lacking TAM67 expression) and
TAM67-expressing mice. These studies reveal a substantial re-
duction in murine involucrin protein in TAM67-expressing
epidermis. This is associated with a 2 to 3-fold increase in
transcription factor binding to the AP1 site in extracts prepared
from TAM67-expressing epidermis. This increase is directly
associated with increased TAM67 level, suggesting that TAM67
is a major factor interacting with the AP1 binding elements in the
epidermis of these mice. TAM67 appears to readily compete jun
family factors off from this site, but appears less efficient at
competing fos family factors. We suspect that this is due preferred
interaction with jun factors and to the somewhat lower level of
TAM67 expression in mouse epidermis as compared to cultured
keratinocytes.
In summary, we describe several findings regarding the
mechanism of TAM67 action in keratinocytes and in TAM67-
expressing murine epidermis. First, our findings suggest that AP1
transcription factors regulate c-jun, junB, junD mRNA and
protein level. Moreover, we show that TAM67 inhibits activity of
the c-jun promoter, suggesting a transcriptional mechanism of
regulation. Second, we show that blocking AP1 factor access to the
hINV gene promoter AP1 factor binding site inhibits transcription,
both in cultured human cells and in vivo in mouse epidermis.
Third, this inhibition appears to be mediated by a ‘‘blocking’’
mechanism where a TAM67 homodimer interacts with the AP1
response element to suppress transcription by preventing endog-
enous jun and fos factor binding to the element (Fig. 8).
Crosslinking experiments suggest the presence of TAM67
homodimers as the major species present in keratinocytes. We
suspect that the balance of TAM67 homodimers versus TAM67
heterodimerzation with endogenous jun and fos factors is depend
upon the concentration of TAM67 expressed. At higher concen-
trations we would expect TAM67 homodimers to be the major
species and that these factors will block endogenous AP1 factor
interaction with DNA. An alternate mechanism, quenching, where
TAM67 forms heterodimers with fos and jun proteins to produce
a transcriptionally inactivate complex at AP1 DNA binding sites, is
also likely. Crosslinking and co-immunoprecipitation experiments
suggest some formation of TAM67 heterodimers with endogenous
AP1 factors. An additional mechanism, called squelching (not
shown), is also possible [26,58,59]. In this mechanism an inhibitor
protein interacts with endogenous factors involved in transcription
regulation that are not bound to DNA [26,58,59]. Although this
may also be a mechanism of TAM67 inhibition, wherein TAM67
sequesters co-activator proteins away from the AP1 binding sites,
we suspect that the major mechanisms whereby TAM67
Figure 8. Mechanism of TAM67 action in keratinocytes. A Wild-
type regulation involves the binding of fos:jun heterodimers (and
jun:jun hetero and homodimers, not shown) to AP1 response element
to drive differentiation-associated gene expression. Blocking occurs
when the concentration of TAM67 present in the cells is high enough
that TAM67 homodimers comprise the major complex bound to DNA
and this complex blocks interaction of endogenous AP1 factors with the
element. Quenching occurs when TAM67 complexes with endogenous
jun and fos factors and this complex, which is transcriptionally inactive,
binds to DNA. We propose that blocking is a major mechanism of
TAM67 action in our system, but that quenching is also important. B
TAM67 interaction at the promoter elements leads to blocking and
quenching to reduce AP1 factor interaction and activity at AP1 binding
sites. This leads to reduced expression of jun factors and ultimately
reduced target gene (involucrin, loricrin) expression.
doi:10.1371/journal.pone.0036941.g008
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and quenching (Fig. 8A) leading to suppression of jun factor and
target gene (hINV, loricrin) expression (Fig. 8B). Our results
suggest that these mechanisms are active both in cultures
keratinocytes and in TAM67-expressing murine epidermis.
Materials and Methods
Cell Culture and Virus Infection
Primary cultures of human newborn foreskin keratinocytes were
cultured in keratinocyte serum-free medium (KSFM) supplemen-
ted with epidermal growth factor and bovine pituitary extract
(10724, Gibco, Invitrogen, Carlsbad, CA). These are obtained as
discarded tissue samples and their use was reviewed and approved
in writing by the University of Maryland Human Subjects
Institutional Review Board. For virus infection, cells were plated
at 40% confluence (0.5 million cells per 21 cm
2 dish) and infected
with 0, 2 or 10 MOI of tAd5-EV or tAd5-TAM67-FLAG in the
presence of 5 MOI of Ad5-TA virus in KSFM containing 6 mg/ml
polybrene (H9268, Sigma, St. Louis, MO). After 6 h the cells were
washed and shifted to fresh virus-free medium.
Immunological Methods and Antibodies
For immunoblot, keratinocytes were washed twice with
phosphate-buffered saline (PBS), drained, and 0.5 ml of lysis
buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4 and
1 mg/ml leupeptin) supplemented with protease inhibitors was
added to each 21 cm
2 (60 mm) dish. After 5 min on ice, the cells
were collected by scraping, and pelleted and sonicated. After
centrifugation at 4uC and 15,0006g for 10 min, protein aliquots
containing 30 mg of protein were separated on denaturing and
reducing Laemmli [60] 8% polyacrylamide gels and transferred to
nitrocellulose. The membrane was blocked in PBS containing 5%
milk powder and 0.1% Tween 20, and incubated at 4uC overnight
with primary antibody and for 1 h at 25uC with horseradish
peroxidase-conjugated secondary antibody. Antibody binding was
visualized using chemiluminescence detection reagent [61].
For anti-FLAG immunoprecipitation, keratinocytes were in-
fected with 10 MOI of tAd5-EV or tAd5-TAM67-FLAG with 10
MOI of Ad5-TA. At 24 h, 200 mg of total cell extract was diluted
to final volume of 500 ml in lysis buffer and pre-cleared by addition
of 25 ml of protein A/G-agarose for 1 h at 4uC. The samples were
then incubated with 20 ml of anti-FLAG M2 affinity gel (Sigma,
A2220) overnight, and the antibody complex was washed three
times with lysis buffer and boiled in 40 ml of Laemmli sample
buffer for electrophoresis.
Immunofluorescence
Keratinocytes, growing on coverslips, were rinsed with PBS and
fixed with 1:1 acetone:methanol for 10 min at 220uC. Cells were
washed three times in PBS for 5 min, and the coverslips were
blocked in 3% bovine serum albumin in PBS for 1 h at room
temperature and then incubated with monoclonal anti-FLAG M2
antibody (F3165, Sigma, diluted 1:1000) for 1 h at room
temperature. Coverslips were washed three times in PBS for
5 min each and incubated with Alexa Fluor 488-conjugated goat
anti-mouse IgG (A11029, Invitrogen, Eugene, OR, diluted 1:1000)
for 45 min at room temperature. Cells were further co-stained
with 2 mg/ml Hoechst 33258 (H3569, Invitrogen) for 5 min,
rinsed in PBS and place in mounting medium (M1289, Sigma).
Fluorescence was visualized using an Olympus OX81 spinning-
disc confocal microscope. No signaling was detected in the absence
of primary antibody.
Antibodies
Rabbit polyclonal antibodies including anti-c-jun (sc-1694,
diluted 1:1000), anti-jun D (sc-746, diluted 1:500), anti-Fra-1
(sc-6056, diluted 1:1000) and anti-Fra-2 (sc-6046, diluted
1:1000), and mouse anti-junB (sc-8051, diluted 1:300) and goat
anti-fosB (sc-482, diluted 1:300) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Rabbit polyclonal anti-c-fos
(ab7963, diluted 1:500) was from Abcam (Cambridge, UK).
Monoclonal anti-FLAG M2-Peroxidase (A8952, diluted 1:3000)
and monoclonal anti-b-Actin (A1978, diluted 1:3000) were
purchased from Sigma (St. Louis, MO). Rabbit anti-human
involucrin (hINV) serum (diluted 1:2000) was produced in our
laboratory [62]. Donkey anti-rabbit (NA934, diluted 1:3000)
and sheep anti-mouse HRP-conjugated secondary antibody
(NA931, diluted 1:3000) were from GE Healthcare (GE
Healthcare, Piscataway, NJ). Donkey anti-goat HRP-conjugated
secondary antibody (sc-2033, diluted 1:3000) was from Santa
Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-loricrin




6 cells) were harvested with trypsin-EDTA,
collected by centrifugation at 5006g and washed several times
with PBS. Nuclear pellet and cytoplasmic fractions were prepared
using Nuclear and Cytoplasmic Extraction Kit (78833, Pierce
Biotechnology, Rockford IL) and stored at 280uC. For protein
crosslinking, the pellet (nuclear fraction, 5610
6 cell equivalents)
was suspended in 100 ml of PBS (pH 8.0) containing 1 mM
disuccinimidyl suberate (DSS, 21555, Pierce, Rockford, IL) and
incubated for 10 min at room temperature. Tris-HCl (1 M, pH 7)
was added to a final concentration of 10 mM to stop the reaction,
and the protein samples were used for gel electrophoresis and
immunoblot.
To prepare nuclear extract from mouse epidermis, skin was
removed and placed on ice and the epidermis was removed by
scraping with a razor blade. Nuclear extract was prepared from
the epidermal tissue using the nuclear and cytoplasmic extraction
kit (78833, Pierce Biotechnology, Rockford, IL) and stored at
280uC.
Chromatin Immunoprecipitation Assay (ChIP)
ChIP assay was performed as described [63] with minor
modification. Keratinocytes (5610
5 cells) from a 35 mm dish were
crosslinked with 1.42% formaldehyde at room temperature for
15 min followed by quenching with 125 mM glycine and then
washed with ice cold PBS containing histone deacetylase
inhibitors. The cells were then lysed in 150 ml of lysis buffer
(50 mM Tris-HCl, pH 8, 10 mM EDTA, 1% SDS, 1 mM PMSF,
20 mM sodium butyrate, and protease inhibitors). Samples were
chilled on ice and DNA was sheared using a Branson Sonifier
(three 30-sec pulses on ice at 40% amplitude with 30 seconds
between pulses to produce fragments of 1,000 bp). Four hundred
microliters of RIPA buffer containing protease inhibitors and
histone deacetylase inhibitors was added followed by a centrifuga-
tion of 12,0006g for 10 min. Aliquots of supernatant containing
sheared chromatin were used for immunoprecipitation. Mouse
monoclonal anti-FLAG (2 mg, F3165, Sigma, St. Louis, MO) was
added to Dynabeads Protein A and incubated for 2 h at 4uC with
rotation at 40 rpm. Sheared chromatin was added and mixture
was incubated at 4uC overnight with rotation. The chromatin-
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of Chelex 100 slurry (10% wt/vol) was added to the washed beads
prior to boiling for 10 min. The samples were then treated with
proteinase K for 30 min at 55uC and boiled for 10 min.
Enrichment of TAM67-FLAG-associated DNA sequences in
immunoprecipitated samples and input samples were detected
by quantitative RT-PCR using sequence specific primers and
LightCycler 480 SYBR Green I Master mix. ChIP primers
included hINV promoter AP1-5 (nucleotides 22218/22055)
forward: 59-TCAGCTGTATCCACTGCCCTCTTT-39 and re-
verse: 59-TCACACCGGTCTTATGGGTTAGCA-39 primers,
and hINV promoter control (nucleotides 21040/2919) forward:
59-CCTCTCAGGGAGAGATTGACATGA-39 and reverse: 59-
CAACAGTGCACCAGCACACTTGAA-39 primers [23].
Gel Mobility Shift Assays
Cells were washed with PBS for preparation of nuclear extract
using NE-PER Nuclear and Cytoplasmic Extraction Reagent
(78833, Pierce Biotechnology, Rockford, IL). Binding of
transcription factors to double-stranded AP1 consensus (AP1c)
oligonucleotide 59-CGCTTGATGAGTCAGCCGGAA-39
(E320A, Promega, Madison, WI, AP1 site in bold) or hINV
AP1-5 probe which encodes the AP1-5 binding site in upstream
regulatory region of human involucrin promoter, 59-
CTTAAGGCTCTTATTATGCCGTGAGTCAGAGGGCGG-
GAGGCAGATCT-39 (AP1 site in bold, Sp1 site underlined)
[50], was monitored by gel mobility shift assay. Three
micrograms of nuclear extract was incubated for 30 min at
room temperature in a volume of 20 ml containing 20 mM
HEPES, pH 7.5, 10% glycerol, 50 mM KCl, 2 mM MgCl2,
0.5 mM EDTA, 0.5 mM DTT, 1 mg/ml poly(dI:dC), 0.1 mg/ml
bovine serum albumin, and 40,000 cpm radioactive double-
stranded AP1c-P
32 or AP1-5-P
32 oligonucleotide. For competi-
tion studies, a fixed molar excess of non-radioactive competitor
oligonucleotide was added to the DNA binding reaction. These
competitors included Sp1 consensus oligonucleotide (Sp1c) 59-
ATTCGATCGGGGCGGGGCGAGC-39 (E323, Promega, Ma-
dison, WI, Sp1 site underlined), AP1c and AP1-5 m/Sp1 m, 59-
CTTAAGGCTCTTATTATGCCGTGAGCCAGAGTCA AG-
GAGGCAGATCT-39 (AP1 site in bold, Sp1 site underlined,
mutant nucleotides shaded) [50]. For gel mobility supershift
assay, 2 mg of antibody specific for FLAG (F3165, Sigma, St.
Louis, MO) or c-jun (sc-456), junB (sc-466), junD (sc-746), Fra1
(sc-6056), Fra-2 (sc-6046), c-fos (sc-2536) and fosB (sc-486) was
added to the reaction mixture and incubated 1 h at 25uC. The
32P-labeled probe was then added and the incubation was
continued for an additional 30 min at 25uC. Protein-DNA
complexes were resolved in 6% polyacrylamide gels under
nondenaturing conditions [8,61].
Quantitative RT-PCR
Total RNA was extracted using Illustra RNAspin Mini Isolation
kit (25-0500-70, GE Healthcare) according to instructions. One
microgram of total RNA was reverse-transcribed to cDNA using
Superscript III reverse transcriptase (18080-093, Invitrogen Inc.)
and random primers (10814270001, Roche, Indianapolis, IN).
Gene expression was measured by quantitative PCR using Roche
LightCycler 480 System and SYBR Green reagents (LightCycler
480 SYBR Green I Master, 04 707 516 001, Roche). RNA level
was normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA level. Relative mRNA level was analyzed by the
comparative CT method. The primers, designed to detect the
indicated genes in mRNA isolated from human keratinocytes,






TAGGGAGGGT-39 [64]; Fra-2 59-CCCTGCACACCCC-
CATCGTG-39/59-TGATTGGTCCCCGCTGCTACTGCTT-
39 [65]; c-jun 59-GTACCTGATGAACCTGATGC-39/59-
GGTCACAGCACATGCCACTT-39 [66]; junB 59-GTCACC-
GAGGAGCAGGAGG-39/59-TCTTGTGCAGATCGTC-




hINV and c-jun Promoter Activity
Human involucrin hINV reporter plasmids, encoding various
lengths of hINV promoter upstream regulatory region fused to the
luciferase reporter gene have been described [36,47]. We used
hINV promoter constructs, pINV-2473, pINV-241, and pINV-41,
which include nucleotides 22473/27, 2241/27 and 241/27,
respectively, of the hINV promoter linked to the luciferase
reporter gene [47]. TAM67 expression plasmid was pcDNA3-
TAM67-FLAG. 12-O-Tetradecanoylphorbol-13-acetate (TPA)
was obtained from Sigma (St. Louis, MO). For experiments,
2610
5 cells were seeded into 35 mm dishes 24 h before trans-
fection. For transfection, 6 ml of Fugene-6 reagent (11 814 443 00,
Roche, Indianapolis, IN) was mixed with 94 ml of KSFM, and
incubated at 25uC for 10 min. This mixture was then added to
1 mg of hINV plasmid and 1 mg of TAM67-FLAG expression
plasmid and incubated at 25uC for 20 min followed by direct
addition to cultures containing 2 ml of KSFM. The final DNA
concentration in all groups was maintained constant by addition of
empty expression vector. At 24 h after transfection, 2 ml of fresh
medium was added containing 0 or 50 ng/ml TPA. After an
additional 24 h, the cells were washed with PBS and scraped into
200 ml of cell lysis buffer, and luciferase activity was assayed
immediately. All assays were performed in triplicate, and each
experiment was repeated a minimum of three times. Luciferase
activity was normalized per microgram of protein. Promoter
activity experiments were also performed in keratinocytes using c-
jun promoter luciferase reporter constructs c-jun(21780/+731)
and c-jun(21780/+731)-AP1 m which encode nucleotides
21780/+731 of the human c-jun promoter and upstream
regulatory region [48]. The latter construct is identical except
that the AP1 sites in the c-jun upstream regulatory region are
mutated [48].
TAM67-rTA Transgenic Mice
The TAM67-rTA mice are maintained in the genetic
background as previously described [35]. These mice harbor
a transgene that encodes TAM67-FLAG linked to a tetracycline-
inducible promoter. Epidermis-specific TAM67-FLAG expres-
sion is induced by addition of 2 mg/ml doxycycline in drinking
water and expression is maximal within two day [35]. A FLAG
epitope is included at the carboxyl terminus of TAM67 so that
expression can be easily monitored. For the experiments
outlined in the present study we utilize 20 wk old female mice
from TAM67-44 strain [35]. Epidermal extracts were prepared
for gel mobility shift or immunoblot after a three day treatment
with doxycycline. Mice were maintained in the University of
Maryland School of Medicine animal facility in compliance with
NIH regulations with laboratory chow and water accessible ad
libitum. The study was approved by the University of Maryland
TAM67 Impact on AP1 Signaling
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Committee.
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